Human neuroblastoma cells acquire regulated secretory properties and different sensitivity to Ca2+ and alpha-latrotoxin after exposure to differentiating agents.
Open Access
- 31 May 1989
- journal article
- research article
- Published by Rockefeller University Press in The Journal of cell biology
- Vol. 108 (6) , 2291-2300
- https://doi.org/10.1083/jcb.108.6.2291
Abstract
IMR-32 human neuroblastoma cells are unable to release [3H]dopamine in response to secretagogues. However, they express a normal complement of membrane receptors and ion channels which are efficiently coupled to second messenger production. In the present study we took advantage of the ability of this cell line to differentiate in vitro in the presence of either dibutyrryl-cAMP or 5-bromodeoxyuridine, to analyze any developmentally regulated changes in its secretory properties. Uptake, storage, and release of [3H]dopamine were studied biochemically and by autoradiography. The calcium ionophore ionomycin, phorbol 12-myristate 13-acetate and the presynaptic acting neurotoxin alpha-latrotoxin were used in both control and differentiated cells as secretagogue agents. The presence of secretory organelles was investigated by electron microscopy; the expression of secretory organelle markers, such as chromogranin/secretogranin proteins (secretory proteins) and synaptophysin (membrane protein), was detected by Western blotting and immunofluorescence. The results obtained indicate that IMR-32 cells acquire regulated secretory properties after in vitro drug-induced differentiation: (a) they assemble "de novo" secretory organelles, as revealed by electron microscopy and detection of secretory organelle markers, and (b) they are able to store [3H]dopamine and to release the neurotransmitter in response to secretagogue stimuli. Furthermore, secretagogue sensitivity was found to be different, depending on the differentiating agent. In fact, dibutyrryl-cAMP treated cells release [3H]dopamine in response to alpha-latrotoxin, but not in response to ionomycin, whereas 5-bromodeoxyuridine treated cells release the neurotransmitter in response to both secretagogues. All together these results suggest that IMR-32 cells represent an adequate model for studying the development of the secretory apparatus in cultured human neurons.This publication has 47 references indexed in Scilit:
- Dopamine release from sympathetic nerve terminalsProgress in Neurobiology, 1988
- ω‐Conotoxin binding and effects on calcium channel function in human neuroblastoma and rat pheochromocytoma cell linesFEBS Letters, 1988
- Intracellular Calcium Homeostasis in a Human Neuroblastoma Cell Line: Modulation by Depolarization, Cholinergic Receptors, and α‐LatrotoxinJournal of Neurochemistry, 1988
- The influence of intracellular calcium concentration on degranulation of dialysed mast cells from rat peritoneum.The Journal of Physiology, 1988
- Endocrine secretory granules and neuronal synaptic vesicles have three integral membrane proteins in common.The Journal of cell biology, 1988
- Characterization of adenohypophysial polypeptides by two-dimensional gel electrophoresis: I. l-[3H]leucine-labeled polypeptidesMolecular and Cellular Endocrinology, 1981
- “Western Blotting”: Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein AAnalytical Biochemistry, 1981
- The participation of α-actinin in the capping of cell membrane componentsCell, 1979
- Human Neuroblastoma Cell Culture: Effect of 5-Bromodeoxyuridine on Morphological Differentiation and Levels of Neural EnzymesExperimental Biology and Medicine, 1973
- Definition of a continuous human cell line derived from neuroblastoma.1970